| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Adams SR et al. | Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. | 2016 | Nat Commun | pmid:27698471 |
| Bergamini A et al. | Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer. | 2016 | Expert Opin Investig Drugs | pmid:27797594 |
| Zhong P et al. | Glutathione-Sensitive Hyaluronic Acid-SS-Mertansine Prodrug with a High Drug Content: Facile Synthesis and Targeted Breast Tumor Therapy. | 2016 | Biomacromolecules | pmid:27723970 |
| Le QA et al. | Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. | 2016 | Breast Cancer Res. Treat. | pmid:27572338 |
| Eckelmann D et al. | Occurrence and spatial distribution of maytansinoids in Putterlickia pyracantha, an unexplored resource of anticancer compounds. | 2016 | Fitoterapia | pmid:27521896 |
| Chen Y et al. | Structural Characterization of Cross-Linked Species in Trastuzumab Emtansine (Kadcyla). | 2016 | Bioconjug. Chem. | pmid:27458087 |
| Li C et al. | Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. | 2016 | Cancer Chemother. Pharmacol. | pmid:27423671 |
| Chen L et al. | In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate. | 2016 | MAbs | pmid:27380163 |
| Gebhart G et al. | Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. | 2016 | Ann. Oncol. | pmid:26598545 |
| Fan Y et al. | Enhancement of UDPG synthetic pathway improves ansamitocin production in Actinosynnem pretiosum. | 2016 | Appl. Microbiol. Biotechnol. | pmid:26585444 |
| Li S et al. | Constitutive overexpression of asm18 increases the production and diversity of maytansinoids in Actinosynnema pretiosum. | 2016 | Appl. Microbiol. Biotechnol. | pmid:26572523 |
| Roviello G et al. | Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. | 2016 | Tumour Biol. | pmid:26566626 |
| Zhang YG et al. | Nocardiopsis ansamitocini sp. nov., a new producer of ansamitocin P-3 of the genus Nocardiopsis. | 2016 | Int. J. Syst. Evol. Microbiol. | pmid:26486850 |
| Hassan R et al. | Mesothelin Immunotherapy for Cancer: Ready for Prime Time? | 2016 | J. Clin. Oncol. | pmid:27863199 |
| Kim SB et al. | Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. | 2016 | Int. J. Cancer | pmid:27428671 |
| Mitsuya K et al. | Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases. | 2016 | BMC Cancer | pmid:27377061 |
| Cilliers C et al. | Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy. | 2016 | AAPS J | pmid:27287046 |
| Martin M and López-Tarruella S | Emerging Therapeutic Options for HER2-Positive Breast Cancer. | 2016 | Am Soc Clin Oncol Educ Book | pmid:27249772 |
| Singh R et al. | A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells. | 2016 | Mol. Cancer Ther. | pmid:27197308 |
| Bellat V et al. | Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release Properties. | 2016 | Biomacromolecules | pmid:27180972 |
| Ogitani Y et al. | Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. | 2016 | Cancer Sci. | pmid:27166974 |
| Feng L et al. | Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. | 2016 | J. Exp. Clin. Cancer Res. | pmid:27102688 |
| Kan S et al. | Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. | 2015 | BMC Cancer | pmid:26475267 |
| Montero JC et al. | Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. | 2015 | Oncotarget | pmid:26336133 |
| Gébleux R et al. | Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates. | 2015 | Mol. Cancer Ther. | pmid:26294742 |
| Goldmacher VS et al. | High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. | 2015 | PLoS ONE | pmid:25671541 |
| Nicoletti R et al. | T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. | 2015 | Clin. Exp. Metastasis | pmid:25398397 |
| Uppal H et al. | Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). | 2015 | Clin. Cancer Res. | pmid:25370470 |
| Krop IE et al. | Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. | 2015 | Ann. Oncol. | pmid:25355722 |
| Yabe N et al. | [A Case of Advanced Breast Cancer in Which Marked Improvement of Joint Pain Was Obtained with Stepwise Dose Reduction of Trastuzumab Emtansine (T-DM1)]. | 2015 | Gan To Kagaku Ryoho | pmid:26805183 |
| Widdison WC et al. | Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing. | 2015 | Bioconjug. Chem. | pmid:26355774 |
| Cosmai L et al. | Renal toxicity of anticancer agents targeting HER2 and EGFR. | 2015 | J. Nephrol. | pmid:26341657 |
| Bartsch R et al. | Activity of T-DM1 in Her2-positive breast cancer brain metastases. | 2015 | Clin. Exp. Metastasis | pmid:26303828 |
| Michel LL et al. | T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. | 2015 | Anticancer Res. | pmid:26254411 |
| Piwko C et al. | Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. | 2015 | Clin Drug Investig | pmid:26123628 |
| Hayashi T et al. | Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. | 2015 | J. Urol. | pmid:26047983 |
| Shen BQ et al. | Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats. | 2015 | Drug Metab Lett | pmid:26031461 |
| Kan S et al. | Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. | 2015 | Oncol. Rep. | pmid:25976081 |
| Dholaria B and Srinivasan S | T-DM1-related carotenoderma and hand-foot syndrome. | 2015 | Lancet | pmid:25933279 |
| Van den Mooter T et al. | Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. | 2015 | Expert Opin Biol Ther | pmid:25865453 |
| Hong EE et al. | Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation. | 2015 | Mol. Pharm. | pmid:25856201 |
| Widdison W et al. | Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. | 2015 | Mol. Pharm. | pmid:25826705 |
| Guerin M et al. | [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]. | 2015 | Bull Cancer | pmid:25790739 |
| Nguyen-Ngoc T and Raymond E | Reinvention of chemotherapy: drug conjugates and nanoparticles. | 2015 | Curr Opin Oncol | pmid:25783982 |
| Mustacchi G et al. | HER2-positive metastatic breast cancer: a changing scenario. | 2015 | Crit. Rev. Oncol. Hematol. | pmid:25748080 |
| Sibaud V et al. | T-DM1-related telangiectasias: a potential role in secondary bleeding events. | 2015 | Ann. Oncol. | pmid:25403586 |
| Yamamoto H et al. | Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. | 2015 | Jpn. J. Clin. Oncol. | pmid:25332421 |
| Baron JM et al. | Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. | 2015 | J Oncol Pharm Pract | pmid:24682654 |
| Singh JC and Lichtman SM | Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. | 2015 | Drugs Aging | pmid:26645293 |
| Hamblett KJ et al. | SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm. | 2015 | Cancer Res. | pmid:26631267 |